These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 32357562)
1. Molecular Drug Discovery of Single Ginsenoside Compounds as a Potent Bruton's Tyrosine Kinase Inhibitor. Lee KW; Lee WH; Han BS; Lee JH; Doo EK; Kim JH Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32357562 [No Abstract] [Full Text] [Related]
2. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors. Sharma A; Thelma BK J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362 [TBL] [Abstract][Full Text] [Related]
4. Development of piperidinyl dipyrrrolopyridine-based dual inhibitors of Janus kinase and Bruton's tyrosine kinase: a potential therapeutic probability to deal with rheumatoid arthritis. Pery N; Rizvi NB; Shafiq MI J Mol Model; 2020 Aug; 26(9):235. PubMed ID: 32808204 [TBL] [Abstract][Full Text] [Related]
5. Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors. Lai MZ; Song PR; Dou D; Diao YY; Tong LJ; Zhang T; Xie H; Li HL; Ding J Acta Pharmacol Sin; 2020 Mar; 41(3):415-422. PubMed ID: 31316181 [TBL] [Abstract][Full Text] [Related]
6. Discovery of Tricyclic Pyranochromenone as Novel Bruton's Tyrosine Kinase Inhibitors with in Vivo Antirheumatic Activity. Cho H; Lee E; Kwon HA; Seul L; Jeon HJ; Yu JH; Ryu JH; Jeon R Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33113810 [TBL] [Abstract][Full Text] [Related]
7. Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold. Teng Y; Lu X; Xiao M; Li Z; Zou Y; Ren S; Cheng Y; Luo G; Xiang H Eur J Med Chem; 2020 Aug; 199():112339. PubMed ID: 32402933 [TBL] [Abstract][Full Text] [Related]
8. Unlocking potential inhibitors for Bruton's tyrosine kinase through in-silico drug repurposing strategies. Alrouji M; Benjamin LS; Alhumaydhi FA; Al Abdulmonem W; Baeesa SS; Rehan M; Shahwan M; Shamsi A; Akhtar A Sci Rep; 2023 Oct; 13(1):17684. PubMed ID: 37848584 [TBL] [Abstract][Full Text] [Related]
9. Discovery of potent and selective reversible Bruton's tyrosine kinase inhibitors. Qiu H; Ali Z; Bender A; Caldwell R; Chen YY; Fang Z; Gardberg A; Glaser N; Goettsche A; Goutopoulos A; Grenningloh R; Hanschke B; Head J; Johnson T; Jones C; Jones R; Kulkarni S; Maurer C; Morandi F; Neagu C; Poetzsch S; Potnick J; Schmidt R; Roe K; Viacava Follis A; Wing C; Zhu X; Sherer B Bioorg Med Chem; 2021 Jun; 40():116163. PubMed ID: 33932711 [TBL] [Abstract][Full Text] [Related]
10. Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development. Liu J; Chen C; Wang D; Zhang J; Zhang T Eur J Med Chem; 2021 May; 217():113329. PubMed ID: 33740548 [TBL] [Abstract][Full Text] [Related]
11. Differential impact of BTK active site inhibitors on the conformational state of full-length BTK. Joseph RE; Amatya N; Fulton DB; Engen JR; Wales TE; Andreotti A Elife; 2020 Nov; 9():. PubMed ID: 33226337 [TBL] [Abstract][Full Text] [Related]
12. Discovery of 5-Phenoxy-2-aminopyridine Derivatives as Potent and Selective Irreversible Inhibitors of Bruton's Tyrosine Kinase. Lee E; Cho H; Lee DK; Ha J; Choi BJ; Jeong JH; Ryu JH; Kang JS; Jeon R Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33126415 [TBL] [Abstract][Full Text] [Related]
13. Discovery of a Novel Class of Covalent Dual Inhibitors Targeting the Protein Kinases BMX and BTK. Forster M; Liang XJ; Schröder M; Gerstenecker S; Chaikuad A; Knapp S; Laufer S; Gehringer M Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291717 [TBL] [Abstract][Full Text] [Related]
14. Discovery of 1-Amino-1 Ma C; Li Q; Zhao M; Fan G; Zhao J; Zhang D; Yang S; Zhang S; Gao D; Mao L; Zhu L; Li W; Xu G; Jiang Y; Ding Q J Med Chem; 2021 Nov; 64(21):16242-16270. PubMed ID: 34672559 [TBL] [Abstract][Full Text] [Related]
15. Discovery of pyrido[3,4-b]indol-1-one derivatives as novel non-covalent Bruton's tyrosine kinase (BTK) inhibitors. Dou D; Sha W; Diao Y; Su R; Qiao Y; Yu Z; Zhao Z; Li H; Chen Z; Xu Y Bioorg Chem; 2022 Feb; 119():105541. PubMed ID: 34910982 [TBL] [Abstract][Full Text] [Related]
16. Discovery of AS-1763: A Potent, Selective, Noncovalent, and Orally Available Inhibitor of Bruton's Tyrosine Kinase. Kawahata W; Asami T; Kiyoi T; Irie T; Kashimoto S; Furuichi H; Sawa M J Med Chem; 2021 Oct; 64(19):14129-14141. PubMed ID: 34529443 [TBL] [Abstract][Full Text] [Related]
17. A Structure-Activity Investigation of the Fungal Metabolite (-)-TAN-2483B: Inhibition of Bruton's Tyrosine Kinase. McCone JAJ; Teesdale-Spittle PH; Flanagan JU; Harvey JE Chemistry; 2024 Jun; 30(35):e202401051. PubMed ID: 38629656 [TBL] [Abstract][Full Text] [Related]
18. Discovery of new non-covalent reversible BTK inhibitors: Synthesis, in silico studies, and in vitro evaluations. Wang Z; Wang S; Kang Y; Chi X; Pan Y; Zeng S; Zhang C; Xu X; Wang W; Huang W Chem Biol Interact; 2024 Nov; 403():111241. PubMed ID: 39278457 [TBL] [Abstract][Full Text] [Related]
19. Bayesian machine learning to discover Bruton's tyrosine kinase inhibitors. Wang J; Ran T; Chen Y; Lu T Chem Biol Drug Des; 2020 Oct; 96(4):1114-1122. PubMed ID: 31855311 [TBL] [Abstract][Full Text] [Related]
20. Structural mechanism for Bruton's tyrosine kinase activation at the cell membrane. Wang Q; Pechersky Y; Sagawa S; Pan AC; Shaw DE Proc Natl Acad Sci U S A; 2019 May; 116(19):9390-9399. PubMed ID: 31019091 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]